Artificial Intelligence Enhances Detection of Multiple Sclerosis Progression for Better Early Treatment
Researchers at Uppsala University have developed an innovative AI model that significantly improves the ability to identify the progression of multiple sclerosis (MS), potentially allowing for more timely and personalized treatment. MS is a chronic neurological disorder affecting about 22,000 individuals in Sweden, typically beginning with the relapsing-remitting form (RRMS), characterized by episodes of deterioration followed by periods of stability. Over time, many patients transition to the secondary progressive form (SPMS), where symptoms worsen steadily without clear relapses. Recognizing this transition promptly is crucial, as the two forms require different treatment strategies. Currently, clinicians typically diagnose this shift approximately three years after it actually occurs, which can delay the start of effective intervention.
The new AI model leverages clinical data from over 22,000 patients registered in the Swedish MS Registry. It analyzes information gathered during regular healthcare visits, such as neurological examinations, MRI scans, and ongoing treatments. By detecting patterns within this data, the AI can accurately distinguish whether a patient still has RRMS or has transitioned to SPMS, with a confidence level indicated for each assessment. This transparency allows healthcare providers to gauge the reliability of the AI's conclusions.
Published in npj Digital Medicine, the study reports that the AI model identified the transition to secondary progressive MS earlier than documented in patients' medical records in nearly 87% of cases, achieving an overall accuracy of approximately 90%. This advancement means that diagnoses can be made sooner, enabling clinicians to adjust treatments earlier and slow disease progression, ultimately improving patient outcomes. Moreover, the model could be instrumental in selecting suitable candidates for clinical trials, fostering the development of more targeted therapies.
An anonymized, open-access version of the model is available via a web platform, supporting researchers worldwide in their efforts to enhance MS care. This development marks a significant step towards more personalized and timely management of multiple sclerosis.
Source: https://medicalxpress.com/news/2025-04-ai-patient-multiple-sclerosis-early.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
New Research Connects Gut Microbiome and Environmental Chemicals to Parkinson's Disease
Recent research uncovers the link between the gut microbiome, environmental chemicals, and Parkinson's disease, highlighting new potential for early diagnosis and targeted therapies through microbiome analysis.
Key Differences in STING Inhibition Between Humans and Mice Uncovered by Researchers
A groundbreaking study uncovers key differences in the STING pathway between humans and mice, influencing future drug development for immune-related therapies. Read about how these discoveries could shape treatments for cancer, neurodegeneration, and autoimmune diseases.
Genetic Insights Reveal Y Chromosome's Role in Determining Male Height Differences
Recent research uncovers the significant role of the Y chromosome in determining male height, independent of sex hormones, highlighting the genetic basis of sexual dimorphism.
Genetic Factors Drive Metastasis Formation in Colorectal Cancer
New research uncovers how genetic mutations in colorectal cancer influence metastasis development, offering potential for personalized treatments targeting organ-specific spread.